SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 12, 2018--
Inc. (NASDAQ: VCYT) announced today that it will report its fourth
quarter and full-year 2017 financial results after the close of market
on Tuesday, February 27, 2018. Following the announcement, Veracyte will
host a conference call and webcast at 4:30 p.m. Eastern Time to discuss
the company's financial results and provide a general business update.
The call may be accessed as follows:
|Veracyte Fourth Quarter and Full-Year 2017 Conference Call,
February 27, 2018 at 4:30 p.m. ET
Dial-in number (U.S.):
The webcast replay will be available on the company's website
approximately two hours following completion of the call and archived on
the company's website.
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is
providing trustworthy and actionable answers that fundamentally improve
patient care when current diagnostic tests are uncertain. The company's
products uniquely combine genomic technology, clinical science and
machine learning to provide answers that give physicians and patients a
clear path forward without risky, costly surgery that is often
unnecessary. Since its founding in 2008, Veracyte has commercialized
three genomic tests, which are transforming the diagnosis of thyroid
cancer, lung cancer and idiopathic pulmonary fibrosis and collectively
target a $2 billion market opportunity. Veracyte is based in South San
Francisco, California. For more information, please visit www.veracyte.com and
follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma
logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180212005185/en/
Tracy Morris, 650-380-4413
Chief Financial Officer